[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].

Yukinori Nakamura, Takehiko Mori, Jun Kato, Yoshinobu Aisa, Tomonori Nakazato, Naoyuki Shigematsu, Shinichiro Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A variety of reduced-intensity conditionings have been used in the reported studies of allogeneic hematopoietic stem cell transplantation (HSCT) for elderly patients with myeloid hematological malignancies. This study retrospectively analyzed the outcome of allogeneic HSCT for 10 patients aged 50 years or older with myeloid hematological malignancies after conditioning with fludarabine (125 mg/m(2)), melphalan (140 mg/m(2)) and total body irradiation (TBI; 8 Gy). Median age of the patients was 56.5 years, and diagnoses included acute myelogenous leukemia, advance myelodysplastic syndrome, and secondary myelofibrosis. Sources of stem cells were bone marrow from sibling (n=4) or unrelated donor (n=6). Both overall and disease-free survival rates were 40.0% (95% CI: 10.6~69.4%). Causes of death were relapse (n=2), fungal infection (n=2), and secondary malignancies (n=2). Because of a high incidence of transplant-related mortality, further refinement of this conditioning is required.

Original languageEnglish
Pages (from-to)318-322
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume53
Issue number3
Publication statusPublished - 2012 Mar
Externally publishedYes

Fingerprint

Melphalan
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Neoplasms
Unrelated Donors
Primary Myelofibrosis
Mycoses
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Disease-Free Survival
Siblings
Cause of Death
Stem Cells
Survival Rate
Bone Marrow
Transplants
Recurrence
Mortality
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{af9886dc10e14032bfa7cbbbf81247e5,
title = "[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].",
abstract = "A variety of reduced-intensity conditionings have been used in the reported studies of allogeneic hematopoietic stem cell transplantation (HSCT) for elderly patients with myeloid hematological malignancies. This study retrospectively analyzed the outcome of allogeneic HSCT for 10 patients aged 50 years or older with myeloid hematological malignancies after conditioning with fludarabine (125 mg/m(2)), melphalan (140 mg/m(2)) and total body irradiation (TBI; 8 Gy). Median age of the patients was 56.5 years, and diagnoses included acute myelogenous leukemia, advance myelodysplastic syndrome, and secondary myelofibrosis. Sources of stem cells were bone marrow from sibling (n=4) or unrelated donor (n=6). Both overall and disease-free survival rates were 40.0{\%} (95{\%} CI: 10.6~69.4{\%}). Causes of death were relapse (n=2), fungal infection (n=2), and secondary malignancies (n=2). Because of a high incidence of transplant-related mortality, further refinement of this conditioning is required.",
author = "Yukinori Nakamura and Takehiko Mori and Jun Kato and Yoshinobu Aisa and Tomonori Nakazato and Naoyuki Shigematsu and Shinichiro Okamoto",
year = "2012",
month = "3",
language = "English",
volume = "53",
pages = "318--322",
journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "3",

}

TY - JOUR

T1 - [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].

AU - Nakamura, Yukinori

AU - Mori, Takehiko

AU - Kato, Jun

AU - Aisa, Yoshinobu

AU - Nakazato, Tomonori

AU - Shigematsu, Naoyuki

AU - Okamoto, Shinichiro

PY - 2012/3

Y1 - 2012/3

N2 - A variety of reduced-intensity conditionings have been used in the reported studies of allogeneic hematopoietic stem cell transplantation (HSCT) for elderly patients with myeloid hematological malignancies. This study retrospectively analyzed the outcome of allogeneic HSCT for 10 patients aged 50 years or older with myeloid hematological malignancies after conditioning with fludarabine (125 mg/m(2)), melphalan (140 mg/m(2)) and total body irradiation (TBI; 8 Gy). Median age of the patients was 56.5 years, and diagnoses included acute myelogenous leukemia, advance myelodysplastic syndrome, and secondary myelofibrosis. Sources of stem cells were bone marrow from sibling (n=4) or unrelated donor (n=6). Both overall and disease-free survival rates were 40.0% (95% CI: 10.6~69.4%). Causes of death were relapse (n=2), fungal infection (n=2), and secondary malignancies (n=2). Because of a high incidence of transplant-related mortality, further refinement of this conditioning is required.

AB - A variety of reduced-intensity conditionings have been used in the reported studies of allogeneic hematopoietic stem cell transplantation (HSCT) for elderly patients with myeloid hematological malignancies. This study retrospectively analyzed the outcome of allogeneic HSCT for 10 patients aged 50 years or older with myeloid hematological malignancies after conditioning with fludarabine (125 mg/m(2)), melphalan (140 mg/m(2)) and total body irradiation (TBI; 8 Gy). Median age of the patients was 56.5 years, and diagnoses included acute myelogenous leukemia, advance myelodysplastic syndrome, and secondary myelofibrosis. Sources of stem cells were bone marrow from sibling (n=4) or unrelated donor (n=6). Both overall and disease-free survival rates were 40.0% (95% CI: 10.6~69.4%). Causes of death were relapse (n=2), fungal infection (n=2), and secondary malignancies (n=2). Because of a high incidence of transplant-related mortality, further refinement of this conditioning is required.

UR - http://www.scopus.com/inward/record.url?scp=84871686217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871686217&partnerID=8YFLogxK

M3 - Article

C2 - 22499048

AN - SCOPUS:84871686217

VL - 53

SP - 318

EP - 322

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 3

ER -